SigNature® DNA Evidence by Applied DNA Used to Convict Criminal in Cash-in-Transit Robbery
January 03 2018 - 8:45AM
Business Wire
Caught “green-blue handed”, Applied DNA secures
first conviction in Ireland
Applied DNA Sciences, Inc. ( NASDAQ: APDN, “Applied DNA”), today
announced that SigNature® DNA evidence has helped to convict a
member of an Irish organized crime group involved in a Cash in
Transit (CiT) robbery.
The robbery in question took place in February 2016. A G4S
cash-in-transit guard was approached by two criminals, one
brandishing a firearm and the other a knife. The criminals escaped
with a stolen cash box in a car driven by Lee Harris, another
member of the robbery team. Harris, a 21-year-old male from Dublin,
dropped off the criminals at the crime scene earlier that day and
kept lookout for police while the robbery took place. Later that
evening, Harris was stopped at a police checkpoint for driving
erratically and was subsequently arrested for drunk driving.
€2,850 in blue/green ink-stained bank notes were found on Lee
Harris and the following day he was charged with armed robbery.
Police contacted Applied DNA to request forensic examination of
bank notes. Within a week, Applied DNA laboratories analyzed
samples and returned an expert witness report to police,
forensically linking the stained bank notes to the specific cash
box stolen during the armed robbery.
Evidence from the expert witness report was used to secure a
conviction against Lee Harris in December 2017. Lawyers acting on
behalf of Harris said he was caught “green-blue handed” with bank
notes that were stained with the security ink containing a
SigNature DNA tag, and he was sentenced to 4 years in prison.
“This is the first criminal conviction in Ireland secured using
SigNature DNA evidence, and should act as a warning to any other
criminals who may be considering a cash-in-transit attack. Our
ever-increasing tally has now reached 115 criminals convicted for
545 years of jail time,” commented Tony Benson, Applied DNA’s
Managing Director for EMEA.
“Also, this demonstrates the fantastic service provided by
Applied DNA and in particular our forensic laboratory team who
analyze these bank note samples quickly, which is often the subject
of special praise,” commented Dr. James Hayward, president and CEO
of Applied DNA.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and DNA mass production for
diagnostics and therapeutics.
We make life real and safe by providing innovative,
molecular-based technology solutions and services that can help
protect products, brands, entire supply chains, and intellectual
property of companies, governments and consumers from theft,
counterfeiting, fraud and diversion. The proprietary DNA-based
“CertainT®” platform can be used to identify, tag, test, and track
products, to help assure authenticity, origin, traceability,
sustainability and quality of products.
SigNature® DNA describes the core technology ingredient that is
at the heart of a family of uncopyable, security and authentication
solutions such as SigNature® T and fiberTyping®, targeted toward
textiles and apparel, BackTrac™ and DNAnet®, for anti-theft and
loss prevention, and digitalDNA®, providing powerful
track-and-trace. All provide a forensic chain of evidence, and can
be used to prosecute perpetrators. Applied DNA Sciences is also
engaged in the large-scale production of specific DNA sequences
using the polymerase chain reaction.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under the symbol
APDN, and its warrants are listed under the symbol APDNW.
Forward Looking Statements
The statements made by APDN in this press release may be
“forward-looking” in nature within the meaning of the Private
Securities Litigation Act of 1995. Forward-looking statements
describe APDN’s future plans, projections, strategies and
expectations, and are based on assumptions and involve a number of
risks and uncertainties, many of which are beyond the control of
APDN. Actual results could differ materially from those projected
due to our short operating history, limited financial resources,
limited market acceptance, market competition and various other
factors detailed from time to time in APDN’s SEC reports and
filings, including our Annual Report on Form 10-K filed on December
28, 2017, which is available at www.sec.gov. APDN undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events or circumstances after the date
hereof to reflect the occurrence of unanticipated events, unless
otherwise required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180103005606/en/
Investors:LHA Investor RelationsSanjay M. Hurry,
212-838-3777shurry@lhai.comorMedia:Dian Griesel Int’lCheryl
Schneider,
212-825-3210cschneider@dgicomm.comorProgram:Applied DNA
EuropeTony Benson, +1 44 (0) 7552 429341Managing
Directortony.benson@adnas.comWeb:
www.adnas.comTwitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024